Free Trial
NYSE:BVS

Bioventus (BVS) Stock Price, News & Analysis

Bioventus logo
$9.61 -0.46 (-4.57%)
Closing price 04:00 PM Eastern
Extended Trading
$9.61 0.00 (0.00%)
As of 04:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Bioventus Stock (NYSE:BVS)

Key Stats

Today's Range
$9.38
$10.03
50-Day Range
$8.76
$11.05
52-Week Range
$3.90
$14.38
Volume
526,102 shs
Average Volume
420,931 shs
Market Capitalization
$779.90 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.00
Consensus Rating
Moderate Buy

Company Overview

Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.

Remove Ads

Bioventus Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
65th Percentile Overall Score

BVS MarketRank™: 

Bioventus scored higher than 65% of companies evaluated by MarketBeat, and ranked 359th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Bioventus has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Bioventus has only been the subject of 1 research reports in the past 90 days.

  • Read more about Bioventus' stock forecast and price target.
  • Earnings Growth

    Earnings for Bioventus are expected to grow by 12.20% in the coming year, from $0.41 to $0.46 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Bioventus is -15.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Bioventus is -15.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Bioventus has a P/B Ratio of 3.43. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for BVS.
  • Dividend Yield

    Bioventus does not currently pay a dividend.

  • Dividend Growth

    Bioventus does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for BVS.
  • News Sentiment

    Bioventus has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 11 news articles for Bioventus this week, compared to 2 articles on an average week.
  • Search Interest

    5 people have searched for BVS on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Bioventus insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $512,511.00 in company stock.

  • Percentage Held by Insiders

    32.90% of the stock of Bioventus is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    62.94% of the stock of Bioventus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Bioventus' insider trading history.
Receive BVS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bioventus and its competitors with MarketBeat's FREE daily newsletter.

BVS Stock News Headlines

Your Wealth is Under Attack
Please don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your free gift, and see how Trump's victory could spark major gains for gold.
Bioventus Shares Rise After Improved 4Q
Bioventus reports Q4 non-GAAP EPS 15c, consensus 8c
Bioventus sees FY25 revenue $560M-$570M, consensus $554.78M
Bioventus Inc. (BVS) Q4 2024 Earnings Call Transcript
See More Headlines

BVS Stock Analysis - Frequently Asked Questions

Bioventus' stock was trading at $10.50 at the beginning of the year. Since then, BVS stock has decreased by 8.5% and is now trading at $9.61.
View the best growth stocks for 2025 here
.

Bioventus Inc. (NYSE:BVS) posted its earnings results on Tuesday, November, 5th. The company reported $0.06 EPS for the quarter, hitting the consensus estimate of $0.06. The company earned $138.96 million during the quarter, compared to analyst estimates of $132.57 million. Bioventus had a negative net margin of 7.11% and a positive trailing twelve-month return on equity of 15.61%.

Bioventus (BVS) raised $126 million in an IPO on Thursday, February 11th 2021. The company issued 7,400,000 shares at $16.00-$18.00 per share. Morgan Stanley, J.P. Morgan, Goldman Sachs and Canaccord Genuity served as the underwriters for the IPO.

Bioventus' top institutional investors include Nantahala Capital Management LLC (4.96%), Vanguard Group Inc. (3.03%), Driehaus Capital Management LLC (1.38%) and American Century Companies Inc. (1.09%). Insiders that own company stock include John A Bartholdson, Juniper Investment Company, Ll, William A Hawkins, Anthony P Bihl III, Mark Leonard Singleton, Anthony D'adamio, John Nosenzo, Robert E Claypoole, Katrina J Church and Kenneth Michael Reali.
View institutional ownership trends
.

Shares of BVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Bioventus investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), ServiceNow (NOW), Adobe (ADBE) and Arista Networks (ANET).

Company Calendar

Last Earnings
11/05/2024
Today
3/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Medical Equipment
Current Symbol
NYSE:BVS
Fax
N/A
Employees
1,200
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$15.00
High Stock Price Target
$17.00
Low Stock Price Target
$13.00
Potential Upside/Downside
+55.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
23.60
P/E Growth
N/A
Net Income
$-156,230,000.00
Pretax Margin
-10.41%

Debt

Sales & Book Value

Annual Sales
$555.06 million
Cash Flow
$0.77 per share
Price / Cash Flow
12.58
Book Value
$2.80 per share
Price / Book
3.46

Miscellaneous

Free Float
54,455,000
Market Cap
$785.17 million
Optionable
Not Optionable
Beta
0.86
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

This page (NYSE:BVS) was last updated on 3/13/2025 by MarketBeat.com Staff
From Our Partners